SAN DIEGO, March 27, 2018 /PRNewswire/ -- Histogen, Inc., a regenerative medicine company developing innovative products from cells grown under simulated embryonic conditions, today announced that Dr. David Crean has been elected to the Company's Board of Directors, and will provide valuable insight as the Company evaluates and completes corporate partnerships in the dermatology and retail sectors.
David H. Crean, Ph.D. has more than 20 years of life sciences research and corporate development transactional experience in the pharmaceutical industry, and has been responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. He currently serves as a Managing Director at Objective Capital Partners, where he leads the firm's life science investment banking transactions.
Prior to joining Objective Capital Partners, Dr. Crean served in specialty pharmaceuticals for companies including Allergan and Aqua Pharmaceuticals, which sold to Almirall, SA. Dr. Crean has led transaction execution in a wide range of specialty areas such as aesthetic and therapeutic dermatology, OTC skin care, neurological disorders, oncology and diagnostics.
"Dr. Crean's industry knowledge and transaction experience make him a tremendous asset to our Board, particularly as Histogen assesses strategic partnerships in key aesthetic markets and new geographies," said Stephen Chang, Ph.D., Chairman of the Board of Directors. "We are delighted to welcome David, and look forward to the Company's continued growth and milestone achievements in 2018."
Dr. Crean's pharmaceutical and biotechnology leadership experience includes serving in key leadership roles in the development and growth of many commercial portfolios including BOTOX, LUMIGAN, JUVEDERM, LATISSE, ACZONE, TAZORAC, MONODOX, FLUOROPLEX, XOLEGEL and VERDESO. Concurrent with Objective Capital, Dr. Crean serves as a strategic business advisor for several life science companies, and is an active member on several industry committees for organizations including BIO International and the Association for Corporate Growth (ACG).
"I am excited to become part of Histogen's Board, especially at a time when both the medical and retail aesthetic markets are growing rapidly and hungry for innovation," said Crean. "Histogen's next generation growth factor technology has been gaining attention in the industry, placing the Company in a position to take advantage of the booming cosmeceutical and aesthetic markets."
Histogen's focus is on the development of high value therapeutic and aesthetic products that stimulate the body's own stem cells to regenerate tissues. In addition to its lead product, Hair Stimulating Complex (HSC), Histogen's growth factor technology has been licensed by Allergan for the physician-dispensed skin care market. Retail skin care is Histogen's next focus for partnership and growth.
Histogen is a regenerative medicine company developing innovative products from cells grown under simulated embryonic conditions, including low oxygen and suspension. Through this unique technology process, newborn cells are directed to naturally produce vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen's technology focuses on stimulating a patient's own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit www.histogen.com.
Contact: Eileen Brandt, 1-858-200-9520, firstname.lastname@example.org
SOURCE Histogen, Inc.